PMID- 35576515
OWN - NLM
STAT- MEDLINE
DCOM- 20220726
LR  - 20230517
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 209
IP  - 1
DP  - 2022 Jul 22
TI  - Cellular immunity in subacute thyroiditis: a new perspective through neopterin.
PG  - 109-114
LID - 10.1093/cei/uxac050 [doi]
AB  - Subacute thyroiditis (SAT) is an inflammatory disorder of the thyroid gland. 
      Although its etiology is not fully understood, it is believed to occur shortly 
      after viral infections and is mostly associated with human leukocyte antigen 
      (HLA)-B*35. Cellular immunity is prominent in SAT. Neopterin is produced by 
      activated monocytes/macrophages and is a marker of cellular immunity. Its 
      production is stimulated by interferon gamma (IFN-gamma), provided mainly by 
      activated helper T lymphocytes type 1 (Th1) in the adaptive immune system. 
      Therefore, with these cells' activation, an increase in serum neopterin levels is 
      expected. We aimed to evaluate neopterin levels in demonstrating cellular 
      immunity in SAT and compared 15 SAT patients with 16 healthy controls. Since all 
      SAT patients were in the active thyrotoxic phase, we found a significant 
      difference in thyroid functions. Classical inflammatory markers, erythrocyte 
      sedimentation rate, and C-reactive protein were markedly elevated in the patient 
      group. Although we expected to find an increase considering that cellular 
      immunity is at the forefront in the pathogenesis of SAT, we found serum neopterin 
      levels significantly lower in the patient group than in the control group. There 
      is an increase in CD8+ T cells in the thyroid tissue in SAT. The possible 
      relationship with HLA-B*35- major histocompatibility complex class I in SAT, and 
      the antigen presentation to CD8+ T cells may be the reason why we observed low 
      serum neopterin levels in patients due to the cytokine imbalance. Neopterin 
      provides unique and independent data from classical acute phase response 
      indicators.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      British Society for Immunology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Sahin Tekin, Melisa
AU  - Sahin Tekin M
AUID- ORCID: 0000-0002-4077-7258
AD  - Department of Internal Medicine, Eskisehir Osmangazi University, Faculty of 
      Medicine, Eskisehir, Turkey.
FAU - Kocaturk, Evin
AU  - Kocaturk E
AD  - Department of Biochemistry, Eskisehir Osmangazi University, Faculty of Medicine, 
      Eskisehir, Turkey.
FAU - Gurcu, Sinem
AU  - Gurcu S
AD  - Department of Pharmacy, Eskisehir City Hospital, Eskisehir, Turkey.
FAU - Kayadibi, Huseyin
AU  - Kayadibi H
AD  - Department of Biochemistry, Eskisehir Osmangazi University, Faculty of Medicine, 
      Eskisehir, Turkey.
FAU - Dibeklioglu, Bilge
AU  - Dibeklioglu B
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Eskisehir Osmangazi University, Faculty of Medicine, Eskisehir, Turkey.
FAU - Yorulmaz, Goknur
AU  - Yorulmaz G
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Eskisehir Osmangazi University, Faculty of Medicine, Eskisehir, Turkey.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 670-65-5 (Neopterin)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Humans
MH  - Immunity, Cellular
MH  - Interferon-gamma
MH  - Neopterin
MH  - T-Lymphocytes, Helper-Inducer
MH  - *Thyroiditis, Subacute
PMC - PMC9307230
OTO - NOTNLM
OT  - CD8+ T lymphocytes
OT  - HLA-B*35
OT  - cytotoxic T cells
OT  - neopterin
OT  - subacute thyroiditis
EDAT- 2022/05/17 06:00
MHDA- 2022/07/27 06:00
PMCR- 2023/05/16
CRDT- 2022/05/16 16:04
PHST- 2022/04/07 00:00 [received]
PHST- 2022/04/27 00:00 [revised]
PHST- 2022/05/10 00:00 [accepted]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/07/27 06:00 [medline]
PHST- 2022/05/16 16:04 [entrez]
PHST- 2023/05/16 00:00 [pmc-release]
AID - 6586515 [pii]
AID - uxac050 [pii]
AID - 10.1093/cei/uxac050 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2022 Jul 22;209(1):109-114. doi: 10.1093/cei/uxac050.